Maxim lowered the firm’s price target on NexGel (NXGL) to $2 from $6 and keeps a Buy rating on the shares. The company’s Celularity acquisition could be transformative for NexGel and turn it into a profitable entity, however the firm is adjusting its price target to reflect the dilution related to the financing for the deal, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXGL:
- NexGel announces terms of agreement of license for products from Celularity
- Celularity reiterates strategic commercialization partnership with NEXGEL
- NexGel Acquires Celularity Regenerative Biomaterials in Transformative Deal
- NexGel sign agreement to license, acquire portfolio of products from Celularity
- NexGel Secures Convertible Note Financing for Acquisition